Koichiro Yoshino Selected Research

3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amide

8/2009

CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-alpha converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Koichiro Yoshino Research Topics

Disease

1	Squamous Cell Carcinoma of Head and Neck 12/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2021
1	Neutropenia 11/2021
1	Colorectal Neoplasms (Colorectal Cancer) 11/2021
1	Myositis (Idiopathic Inflammatory Myopathies) 07/2012
1	Rheumatoid Arthritis 07/2012
1	Retinal Neovascularization 08/2009
1	Retinopathy of Prematurity (Retrolental Fibroplasia) 08/2009
1	Diabetic Retinopathy (Retinopathy, Diabetic) 08/2009
1	Ischemia 08/2009
1	Pathologic Neovascularization 08/2009

Drug/Important Bio-Agent (IBA)

1	Histamine (Histamine Dihydrochloride)FDA Link 12/2021
1	Fluorouracil (Carac)FDA LinkGeneric 12/2021
1	lafutidineIBA 12/2021
1	tipiracilIBA 11/2021
1	trifluridine tipiracil drug combinationIBA 11/2021
1	Bevacizumab (Avastin)FDA Link 11/2021
1	Trifluridine (Viroptic)FDA LinkGeneric 11/2021
1	AntibodiesIBA 07/2012
1	AutoantibodiesIBA 07/2012
1	Jo-1 antibodyIBA 07/2012
1	Oxygen (Dioxygen)IBA 08/2009
1	Matrix Metalloproteinases (MMPs)IBA 08/2009
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2009
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2009
1	ADAM17 ProteinIBA 08/2009
1	3,4,5- trihydroxy- 1- (4'- phenoxybenzenesulfonyl)piperidine- 2- hydroxy amideIBA 08/2009

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 11/2021